Alterity Therapeutics Ltd

PBN

Company Profile

  • Business description

    Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson’s disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.

  • Contact

    350 Collins Street
    Suite 4, Level 14
    MelbourneVIC3000
    AUS

    T: +61 393494906

    E: [email protected]

    https://www.alteritytherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    9

Stocks News & Analysis

stocks

BlackRock earnings: Market gains and inflows drive AUM and revenue to record highs

We plan to raise our fair value estimate of BlackRock stock.
stocks

Our view of ANZ’s strategic plan

Trying to please customers and shareholders with a simpler and leaner bank.
stocks

Perplexing buyback from overvalued ASX share

Earnings continue to grow but investor expectations are too high.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,299.0021.900.24%
CAC 408,127.44207.822.62%
DAX 4024,317.0080.060.33%
Dow JONES (US)46,270.46202.880.44%
FTSE 1009,434.6518.12-0.19%
HKSE25,910.60469.251.84%
NASDAQ22,521.70172.91-0.76%
Nikkei 22547,672.67825.351.76%
NZX 50 Index13,307.4030.410.23%
S&P 5006,644.3110.41-0.16%
S&P/ASX 2008,990.9022.200.25%
SSE Composite Index3,912.2146.981.22%

Market Movers